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Captopril inhibits the hydroosmotic effect of ADH
in the cortical collecting tubule
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Captopril inhibits the hydroosmotic effect of ADH in the cortical
collecting tubule. Previous studies have shown that captopril (CP)
inhibits ADH-stimulated osmotic water permeability (Pt) in the toad
bladder by potentiating endogenous bradykinin (BK). The present
studies examine the effect of CP on ADH-stimulated P1 in isolated,
perfused rabbit cortical collecting tubules (CCT). CP (10 " M) revers-
ibly inhibited P1, stimulated by maximal concentrations of ADH (10
j.tU/ml). Pretreatment of CCT's with 5 M indomethacin, however,
abolished the effect of CP. Inhibition of BK production by the kallikrein
inhibitors, aprotinin and benzamidine, failed to enhance P1 stimulated
by submaximal concentrations of ADH (2.5 Ufml). Since ADH exerts
its effects by activation of adenylyl cyclase (AC), further experiments
were performed to identify the site at which CP inhibits this cascade.
CP significantly inhibited forskolin (l0 M) stimulated P1; however, it
had no effect on cyclic AMP (10 M) stimulated P1, suggesting that the
site of action is on the catalytic subunit or one of the GTP regulatory
proteins of AC. To further localize the site of CP's action, CCT's were
pre-incubated with pertussis toxin (0.5 g/ml) to inactivate the inhibi-
tory, guanosine trihosphate (GTP) regulatory protein, Oi. In these
tubules, CP failed to inhibit the action of ADH. We conclude that CP
stimulates prostaglandin production which in turn activates G1 and
inhibits AC activity. We further suggest that CP stimulates PG's
directly, not via BK.
There is growing evidence that a number of neurohumoral
agents modulate the renal handling of salt and water by direct
effects on the tubular transport mechanisms. Of recent interest
is the control of ADH-dependent osmotic fluid absorption in the
cortical collecting tubule.
Using the isolated, perfused tubule technique, our laboratory
has demonstrated that catecholamines inhibit the hydroosmotic
effect of ADH via an a2-adrenergic receptor [1, 21. Another
agent, bradykinin, has also been shown to attenuate the action
of ADH in the toad bladder [3] and isolated, cortical collecting
tubule [4]. In these two studies, bradykinin was added to the
bathing medium. Evidence for a similar effect of endogenous
bradykinin has also been shown. Carvounis et al [5] have shown
that captopril, which inhibits kininase II as well as angiotensin
converting enzyme, attenuates the action of ADH in the toad
bladder. When these authors exposed the bladders to a kallik-
rein inhibitor, aprotinin, the hydroosmotic effect of submaximal
ADH concentrations was enhanced. They concluded that cap-
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topril inhibits the action of ADH by potentiating endogenous
bradykinins.
Clinical studies have also suggested a role for bradykinins in
the control of ADH action. In patients with congestive heart
failure and hyponatremia, captopril administration returned
serum sodium to normal values [6, 7]. This effect was indepen-
dent of the improvement in cardiac output since other agents,
which affected the same degree of improvement, did not correct
the hyponatremia [7]. This suggests that captopril may directly
modulate either the hydroosmotic effect of ADH or its rate of
secretion.
Because of these observations, we have designed studies to
determine the effect of captopril on the hydroosmotic effect of
ADH in the isolated cortical collecting tubule. Once an effect
was defined, the mechanism of action of captopril was then
examined.
Methods
Segments of cortical collecting tubules (CCT) were isolated
and perfused in vitro as previously described [1, 2]. Briefly,
experiments were performed on female, New Zealand white
rabbits, weighing 1.5 to 2.0 kg, maintained on tap water and
standard rabbit chow until sacrificed by decapitation. The left
kidney was quickly removed, decapsulated and sliced into 1
mm transverse sections. The sections were placed in a dish
containing a chilled solution with the following composition (in
mmollliter): NaCl, 140; K2HPO4, 2.5; MgSO4, 1.2; L-alanine,
6.0; Na citrate, 1.0; Na lactate, 4.0; CaCl2, 1.8; and glucose,
5.5. The pH was maintained at 7.4, by gassing with 5% C02,
95% 02; osmolality was 290 mOsm/kg H20; and 0.25 g/dl
defatted bovine albumin was added to prevent adhesion of
tissue to the dissection dish. Segments of CCT were dissected
free, transferred to a lucite perfusion chamber and perfused in
vitro as described by Burg and colleagues [8]. The tubule
segments were bathed with the solution described above,
exchanged continuously at 0.5 ml/min, and maintained at 25° C.
The perfusion solution, driven by a gravity flow system at 8 to
14 nllmin, had the following composition (in mmollliter): NaCI, 60;
K2HPO4, 2.5; MgSO4, 1.2; and CaC12, 1.8. The pH was 6.2 and
osmolality 125 m0smlkg. Exhaustively dialyzed [methoxy-3H]
inulin (ICN; Irvine, California, USA) was added to the perfus-
ing solution as a volume marker.
Following the initiation of perfusion, an equilibration period
of 120 to 150 minutes was allowed to ensure the disappearance
of the effects of endogenous vasopressin. Timed samples were
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collected under oil using constant-volume constriction pipettes
advanced into the collecting pipette. These samples were then
placed in counting vials containing 10 ml of Biofluor (New
England Nuclear, Boston, Massachusetts, USA) and 3H radio-
activity measured in a Tri-carb liquid scintillation counter
(Packard Instrument Co. Inc., Downers Grove, Illinois, USA).
(Arg8)-vasopressin (AVP) acetate, 8-bromo-cyclic AMP, apro-
tinin, benzamidine, and indomethacin were obtained from Sigma
Chemical Co (St. Louis, Missouri, USA), and forskolin was
obtained from Cal Biochem (division of Behnng Diagnotics,
San Diego, California, USA). Captopril was from E.R. Squibb
and Sons Inc. (Princeton, New Jersey, USA). Stock solutions
of these agents were prepared daily and added to the bathing
solution, to the final concentration, just prior to the experiment.
An equilibration period of 30 to 60 minutes was allowed after
the addition of these agents to the bathing solution.
Seven groups of experiments were performed as follows:
Group I. Six CCT segments (mean length 1.1 0.1 mm)
served as time controls. Following the equilibration period,
control collections were obtained and then AVP, 10 pU/mi, was
added to the bath. This concentration of AVP has been shown
previously to maximally stimulate Jv [1]. Two sets of collec-
tions were obtained, one set after 60 minutes of AVP, another
after 120 minutes.
Group II. In five CCT segments (mean length, 0.9 0.1 mm),
after the initial equilibration period, control collections were
obtained. AVP, 10 pU per ml, Was then added to the bathing
solution, and after 40 to 60 minutes collections obtained.
Captopril to a final concentration of iO M was then added to
the bath containing AVP, and additional collections obtained.
This concentration of captopril maximally stimulates prosta-
glandin synthesis in renal cells in culture [9]. Finally, the bath
containing only AVP was reinstated, and further collections
obtained.
Group III. Four CCT segments (mean length 1.0 0.04 mm)
were pretreated with indomethacin, 5 prs, in the bathing
solution during the 120 to 150 minute equilibration period and
collections obtained to determine its effect on basal Jv. The
remainder of the protocol was similar to that for Group II,
except the final period was omitted.
Group IV. For 10 CCT segments the initial bathing solution
contained 2.5 pU/ml AVP, which has been shown to stimulate
fluid absorption below the maximal rate [11. After initial collec-
tions were made, five tubules (mean length, 0.9 0.2 mm) were
exposed to 10-6 to iO M aprotimn in the perfusate, and 5
(mean length 1.7 0.2 mm) to 3 x i0 M benzamidine in the
bath containing AVP and further collections were obtained. The
bath containing only AVP was then reinstated and final collec-
tions obtained. The concentrations of aprotinin were based on
previous studies in toad bladder [5]; the concentration of
benzamidine chosen was lower than the 1 to 30 mivi concentra-
tions used previously [10, 11].
Group V. Eight CCT segments (mean length 1.1 0.1 mm)
were studied in a similar manner as Group II except that instead
of AVP, forskolin was added to the bath to a final concentration
of iU M, as per previous studies [12, 13], and the fourth period
was omitted.
Group VI. Five CCT segments (mean length 1.2 0.2 mm)
were studied as in Group II except 8-bromo-cyclic AMP, iO
M, shown to be effective in a previous study [1], was added to
the bath instead of AVP, and the fourth period was omitted.
Group VII. In this group of five CCT segments (mean length
1.7 0.2 mm), after the initial equilibration period and control
collections, pertussis toxin (PT), 0.5 pg/ml, was added to the
bath. Following a 60 minute exposure to PT, additional collec-
tions were obtained. Further collections, as in Group II, were
obtained after the addition of AVP (10 pU/ml) and after AVP
and captopril (10-a M) addition to the bath containing PT.
Calculations
Net fluid absorption, Jv, (nlIminlmm) was calculated from the
following formula: Jv (Vi — Vo)/L, where Vi and Vo are the
tubular fluid perfusion rate and collection rate, respectively, in
nl/min; and L is the length of the tubule in mm measured by a
reticle in the eyepiece of the microscope. Vi and Vo are
calculated from the 3H inulin concentration as described previ-
ously [1].
In order to eliminate the influence of perfusion rate on Jv, the
osmotic water permeability, Pf, in cm/sec was calculated by the
following formula:
ViCi F Ci — Co 1 (Co— Cb)(Ci)pf_ — I +—ln
A Vw LCi . Cb Co (Cb)2 (Ci — Cb)(Co)
where A is the area of the tubule (cm2); Vw, the partial molal
volume of water (cm3/mmole); Ci, Cb and Co, the osmolality of
the perfusate, bath and collected fluid (mOsm/kg), respectively.
Ci and Cb were measured directly on an Advanced Instruments
(Needham heights, Massachusetts, USA) osmometer. Co was
calculated from the relationship ([3Ho]/[3Hi]) x (Ci), where 3Ho
and 3Hi are the inulin disintegrations per minute per nanoliter
for the collected and perfused fluid, respectively.
All values represent the mean SE of three to four collec-
tions for each experimental period, for each tubule. Statistical
analysis was performed using analysis of variance.
Results
Group I
In this group of tubules, after the initial equilibration period,
iv was —0.05 0.10 ni/mm/mm and Pf was —10 10 x i0
cm/sec. neither value is different from zero. After exposure to
10 /LU/ml AVP in the bath iv had significantly increased to 0.81
0.09 after one hour, and 1.13 0.16 nl/min/mm after two
hours. Likewise Pf increased to 77 10 and 105 19 cm/sec x
iO after one and two hours AVP, respectively. The values for
Jv and Pf after two-hour exposure are significantly increased
from the values after one hour.
Group II
As in Group I, iv and Pf were no different from zero after the
initial equilibration period, Jv being 0.04 0.06nl/min/mm and
Pf being 3 7 x lO cm/sec. The remaining results from this
group are shown in Fig. 1. With the addition of AVP to the bath
iv increased significantly to 1.06 0.12 nllmin/mm and Pf to 89
12 x i0 cm/sec. Mter the further addition of captopril to
the bath Jv declined to 0.45 0.12 nl/min/mm and Pf to 44 12
x i04 cm/sec. These values are significantly lower than with
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AVP alone but remain higher than control values. After re-
moval of captopril Jv and Pf returned to values comparable to
those observed in the previous period with AVP alone, being
1.24 0.10 and 117 11, respectively.
Group III
In these tubules, 2 to 2-1/2 hours of exposure to indomethacin
had no effect on baseline Jv and Pf(Fig. 2), being —0.09 0.14
nhlmin/mm and —7 11 x i0 cm/sec, respectively. Alter the
addition of AVP Jv increased significantly to 1.60 0.24 and P1
to 157 25. After the addition of captopril Jv and Pf did not
decrease, being 1.63 0.24 nhlminlmm and 154 12 X iO
cm/see, respectively.
Group IV
In these tubules, after 2 to 2-1/2 hours of exposure to 2.5 U
AVP in the bath, Jv was 0.53 0.08 and 0.63 0.14 nl/min/mm
in the aprotinin and benzamidine subgroups, respectively.
Likewise P1 was 50 9 and 49 7 x l0 cm/sec for these two
subgroups. With the addition of aprotinin to the perfusate Jv fell
significantly to 0.30 0.09 and P1 to 26 12, and following the
Jv
Control
0.10 0.04
F(104 M)
1,50 0.27a
F(104 M) +
CP(l04M)
0.73 026a,b
P1 8 5 145 27 69 25
Control cAMP l0 M
cAMP iO M +
CP l0— M
Jv —0.09 0.11 1.74 0.2? 1.71 0.22a
Pf 7 11 165 2? 164 22
PT 0.5 pg/
PT0.5.g/ ml+AVP1O
Control PT 0,5 g/ml
ml + AVP 10
U/ml
U/ml
+ CP lO M
Jv 0.15 0.03 0.40 0.10 1.50 021a,b 1.31 0.24"
P1 14 4 37 4 156 28' 134 26a,b
Jv and P1 are described in Table 1.
a P < 0.05 vs. control
b p < 0.05 vs. PT alone
removal of aprotinin Jv and P1 failed to recover, being 0.31
0.04 nl/min/mm and 26 6 x l0— cm/see, respectively. In the
tubule segments exposed to benzamidine in the bath, Jv de-
creased to 0.15 0.04 nI/mm/mm and P1 to 14 4 x lO
cm/sec and failed to recover upon its removal, Jv being 0.10
0.11 and P1 being 10 11.
Group V
As in Group II, Jv and P1 were no different from zero after the
initial equilibration period (Table 1). The addition of forskolin to
the bath significantly increased Jv and P1. The subsequent
addition of captopril significantly decreased Jv and P1, how-
ever, both values remained higher than control.
Group VI
In this group of tubules, again Jv and P1 were no different
from zero in control, increased significantly with the addition of
8-Br-cAMP to the bath and failed to decline with the subsequent
addition of captopril (Table 2).
Group VII
In this group, the initial Jv and P1 were very low, although
significantly different from zero (Table 3). Incubation with
pertussis toxin for one hour appeared to stimulate Jv and P1,
however, the increase above control values was not statistically
significant. The addition of AVP significantly enhanced Jv and
N= 5
150
200 Table 1. Effect of captopril (CP) on forskolin (F) stimulated Jv and P1
(N =8)
'100
50
AVP1Op.U/mI AVP10U/mI AVP10U/ml
CP 104M
2.0
1.5
1.0
0.5
0
Fig. 1. The effect of captopril (CP) on the hydroosmotic action of (A rg8)-
vasopressin (A VP) in cortical collecting tubule segments. *Denotes a
statistically significant difference as compared to the first period with
AVP alone. Symbols are: (E) Jv nl/min/mm; () P1 X iO cm/sec.
2.0
1.5
1.0
0.5
0
—0.5
Jv is net volume absorption in nI/mm/mm and P1 is the osmotic water
permeability coefficient, in x 10" cm/sec.
a p < 0.05 vs. control
' P < 0.05 vs. forskolin alone
Table 2. Effect of captopril (CP) on 8-Br-cAMP stimulated Jv and P1
(N=5)
N= 4 For explanation of terms, see Table
a p < 0.05 vs. control
Table 3. Effect of captopril (CP) on AVP stimulated Jv and P1 in the
presence of pertussis toxin (PT) (N = 5)
ND 5M IND Sp.M IND 5M
AVP 10tU/mI AVP 10U/ml
CP 104M
Fig. 2. The effect of captopril on the hydroosmotic action of AVP in
tubule segments pretreated with indomethacin (IND). *Denotes a
statistically significant difference from the period with indomethacin
alone. Symbols are the same as Figure 1.
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Pf, which remained increased with the subsequent addition of
captopril.
Discussion
Recent evidence has suggested an important role for the renal
kallikrein-kinin system in salt and water homeostasis. Two in
vitro studies have shown a direct effect of exogenous bradyki-
nm on ADH-stimulated water flow in fluid-transporting epithe-
ha [3, 41. A third study in the toad bladder has shown that
inhibition of kininase, with captopril, mimics the effects of
exogenous bradykinin, probably by potentiating the intracellu-
lar concentration of this hormone [51. Because of this latter
study and clinical evidence for a similar effect on ADH action in
vivo, the present studies were undertaken to characterize the
action of captopril in isolated perfused, rabbit cortical collecting
tubules.
The results of this study clearly show that the addition of
captopril to the peritubular bathing solution significantly atten-
uates the hydroosmotic effect of ADH. Furthermore, prosta-
glandin generation appears to mediate the action of captopril
since pretreatment of the tubule segments with indomethacin
totally blocked captopril's effect. Because captopril inhibits
kininase II, which in turn could raise endogenous bradykinin
levels, and since bradykinin exerts its effect via the prostaglan-
dins [4, 5], these results suggest that bradykinin mediates the
action of captopril. Assuming, then, that endogenous bradyki-
nm normally modulates ADH action, as found in the toad
bladder [5], we studied the effect of kallikrein inhibitors on fluid
absorption stimulated by submaximal concentrations of ADH.
Instead of producing the anticipated enhancement of the effect
of ADH, these agents, aprotinin and benzamidine, irreversibly
inhibited fluid absorption. There are three possible explanations
for these findings. Firstly, these agents are not specific for
kallikrein but inhibit other serine proteases, and thus may have
inhibited some other intracellular mechanism(s) necessary for
fluid absorption to proceed. Secondly, endogenous levels of
bradykinin may not have an inhibitory effect on ADH action.
Thirdly, there may be little if any bradykinin production in the
cells of the cortical collecting tubule. With regard to the last two
possibilities, recent studies have shown binding of [3H] brady-
kinin to be highest in the cortical collecting tubule of the rabbit
nephron [141. These studies are consistent with the observa-
tions of Schuster, Kokko and Jacobson [4] showing that exog-
enous bradykinin inhibits the action of ADH in cortical collect-
ing tubule segments. However, active and inactive kalhikrein
concentrations are very low in this segment [15, 16], the highest
concentration of kallikrein being localized to the granular
portions of the distal convoluted and cortical collecting tubule
segments (connecting tubule segment). These latter studies may
explain the lack of effect of the kallikrein inhibitors in our study.
Since kininogen was absent from the solutions bathing the
perfused tubules, and kallikrein concentration is low in the
cortical collecting tubule, it is reasonable to assume that the
endogenous production of bradykinin is insignificant in this in
vitro model. Also, if endogenous bradykinin concentration is
low or nonexistent, one would not expect to observe a tonic
inhibitory effect on ADH action. Thus, the results seen with the
kalhikrein inhibitors most likely reflect non-specific inhibition of
other cellular serine proteases. Furthermore, it would appear
from the foregoing that bradykinin does not mediate the action
of captopril in our in vitro model.
Since we contend that bradykinin does not mediate the action
of captopril in our experiments, the question arises as to how
captopril stimulates prostaglandin E synthesis. In fact, capto-
pril has been shown to increase arachidonate release and
prostaglandin synthesis in vivo [17—21], as well as in renomed-
ullary, interstitial cell cultures [9], and isolated renal glomeruli
and aortic strips [22]. Additionally, the stimulation of bradyki-
nm production by captopril may be secondary to the stimulation
of prostaglandin synthesis [23]. Finally, the effects of both
captopril and bradykinin on prostaglandin synthesis exceed the
separate effects of each agent alone [9], suggesting a direct
effect of captopril on prostaglandin generation. This additional
evidence lends credence to our proposal that in our experiments
captopril directly stimulates prostaglandin synthesis which then
attenuates the action of ADH.
It is generally accepted that ADH exerts its actions through
the generation of cyclic AMP in the cortical collecting tubule
[24]. Thus, experiments were designed to determine where in
the adenylyl cyclase-cychic AMP-cascade captopril exerts its
effects. Since captopril-attenuated fluid absorption stimulated
by forskolin and not by 8-Br-cyclic AMP, the site of inhibition
must be at the catalytic subunit or at one of the GTP-binding
proteins which regulate adenylyl cyclase. To investigate this
possibility, we pretreated tubule segments with pertussis toxin,
which irreversibly ADP-ribosylates the a-subunit (ai) of the
inhibitory regulatory protein, Gi [25]. In these studies, captopril
failed to attenuate the hydroosmotic effect of ADH, suggesting
that captopril exerts its effect by activating Gi which then turns
off the catalytic subunit, inhibiting cyclic AMP production. This
sequence of events results in an attenuation of ADH action.
The action of captopril to inhibit forskolin-stimulated Pf, if
exerted via prostaglandin production, is in direct variance with
the results of Nadler, Hebert and Brenner [26]. This study
showed no effect of PGE2 addition, to the bath, on the hydro-
osmotic effect of 1 or 10 M forskohin. This discrepancy
suggests that the action of captopril in the present study is not
mediated by prostaglandins. Coupled with the lack of effect on
captopril on cAMP-stimulated fluid absorption, one might con-
clude that captopril stimulates phosphodiesterase activity. How-
ever, the experiments using indomethacin pretreatment suggest
that this is not the mechanism, since the concentration of
indomethacin used inhibits phosphodiesterase activity mini-
mally [27], and even 100% inhibition of this enzyme has little
effect on basal or stimulated fluid absorption in the toad bladder
[27—29], and rat renal medullary tissue [30]. Thus, if captopril
exerts its effects via stimulating phosphodiesterase activity,
indomethacin would not be expected to inhibit the action of
captopril. It is possible that captopril produces a higher, more
effective intracellular concentration of PGE2 in the present
studies than was achieved in the studies of Nadler et al [26].
The attenuation of captopril-inhibition of AVP by pretreat-
ment with pertussis toxin is not at variance with the forskohin
data. Forskolin is not an irreversible stimulant of adenylyl
cyclase activity, as previous studies have shown that inhibition
of Gi with pertussis toxin reverses GTP and Gpp(NH)p inhibi-
tion of basal- and forskolin-activated adenylyl cyclase activity
[31—33]. These observations lend credence to the mechanism
proposed in this study. In another study from this laboratory,
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similar experiments have shown that pretreatment of CCT's
with pertussis toxin also reverses the inhibition of AVP action
by clonidine [34].
In summary, captopril has been shown to have a direct action
on the cortical collecting tubule to inhibit the hydroosmotic
effect of ADH. The sequence of events, suggested by our study,
involves the direct stimulation of prostaglandin synthesis; pros-
taglandins then stimulate the inhibitory regulatory protein of
adenylyl cyclase inhibiting cyclic AMP generation and attenu-
ating fluid absorption. This action of captopril may be the
mechanism by which this angiotensin converting enzyme-inhi-
bitor corrects the hyponatremia of congestive heart failure [6,
7].
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